In a study published in Nature Communications, Dr. Eiji Yoshihara, PhD, investigator at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center and an assistant professor at the David Geffen School of Medicine at UCLA, and his team reported the discovery of a key marker, FXYD2, that identifies both the functional maturity and heterogeneity of stem cell–derived islet organoids. This breakthrough enables researchers to distinguish between “good” and “bad” quality islets, providing a much-needed tool for quality control in the production of transplantable islets. The current study represents a key next step shifting from generation to functional selection and advances the field toward safer and more effective islet replacement therapies. 

Dr. Lee Seongsoo’s research group at the Honam Regional Center of the Korea Basic Science Institute (KBSI) successfully observed and quantitatively analyzed the antibacterial and antibiofilm activity of multidrug-resistant bacteria (MDR-bacteria or superbacteria) in real time using three-dimensional holotomography (3D HT*) technology.Dr. Lee Seongsoo’s research group at the Honam Regional Center of the Korea Basic Science Institute (KBSI) successfully observed and quantitatively analyzed the antibacterial and antibiofilm activity of multidrug-resistant bacteria (MDR-bacteria or superbacteria) in real time using three-dimensional holotomography (3D HT*) technology.